HeyJaredOncotarget
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.Read about…
- Indexed episodes, last 90 days
- 14
- Latest publication
- Sep 9, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 6, 2026
Latest episodes
Restoring MHC-I Expression Could Strengthen Immune Responses Against CNS Cancers (opens the original)
Read excerpt
BUFFALO, NY – September 9, 2026 – A new #review was #published in Volume 17 of Oncotarget on September 8, 2026, titled “Re-expression of MHC-I to treat CNS cancers.” The review examines emerging strategies to restore major histocompatibility complex class I (MHC-I) expression in cancers of the central nervous system (CNS), with the goal of making these tumors more visible and vulnerable to immune attack. The review was authored by Arseniy E. Yuzhalin from the Sirius University of Science and Tec
Therapeutic HPV Vaccine PepCan Tested for Preventing Head and Neck Cancer Recurrence (opens the original)
Read excerpt
Head and neck squamous cell carcinoma (HNSCC) can return even after patients complete surgery, radiation, chemotherapy, or combinations of these treatments. Preventing recurrence therefore remains an important challenge in head and neck cancer care. Human papillomavirus (HPV), particularly HPV type 16, is also an established cause of a subset of these cancers, especially oropharyngeal squamous cell carcinoma. A research paper published in Volume 17 of Oncotarget, titled “A randomized double-blin
Oncotarget Supports WIN 2026 Symposium Advancing Precision Oncology (opens the original)
Read excerpt
BUFFALO, NY - September 8, 2026 – Oncotarget is proud to support the WIN 2026 Symposium, organized by the Worldwide Innovative Networking (WIN) Consortium, taking place October 2–3, 2026, at the Rhode Island Convention Center in Providence. The two-day symposium, themed “Precision Oncology: Innovation and Equity Across the Globe,” will bring together researchers, clinicians, healthcare professionals, industry leaders, and other experts from around the world to explore advances in precision oncol
Tumor-Derived Extracellular Vesicles Show Promise for Earlier Detection of Metastatic Risk (opens the original)
Read excerpt
BUFFALO, NY – September 1, 2026 – A new #review was published in Volume 17 of Oncotarget on August 28, 2026, titled “Emerging biomedical imaging applications of tumor-derived extracellular vesicles for premetastatic niche detection: Biological rationale, engineering strategies, and translational challenges.” The review was led by first author Omkar Dhaygude, who is affiliated with Johns Hopkins University. Corresponding authors Franck Housseau and John Michel are affiliated with Johns Hopkins Un
Tumor-Infiltrating Lymphocyte Therapy Offers a Promising Approach for Treating Solid Tumors (opens the original)
Read excerpt
BUFFALO, NY – August 31, 2026 – A new #editorial was published in Volume 17 of Oncotarget on June 8, 2026, titled “Tumor infiltrating lymphocyte (TIL) therapy for treating the solid tumors: Challenges and future perspectives.” The editorial was led by first and corresponding author Bhartendra Sharma from Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India, along with co-authors Sukhbir Kaur, Vikas Sharma and Sanjay Soni. Tumor-infiltrating lymphocyte (TIL) ther
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.